Business UpdateMay 18, 2026, 08:02 AM
Protara Therapeutics to Host Investor Webinar on TARA-002 & LMs
AI Summary
Protara Therapeutics, Inc. announced it will host a virtual webinar for the investment community on Tuesday, May 19, 2026, at 4:30 pm ET. The event will provide an overview of Lymphatic Malformations (LMs), the current treatment landscape, and the TARA-002 clinical program. It will also feature key opinion leader perspectives, discuss the market opportunity and regulatory path for TARA-002, and review supporting clinical data. TARA-002 holds multiple FDA designations, including Rare Pediatric Disease, Orphan Drug, Breakthrough Therapy, and Fast Track for LMs.
Key Highlights
- Protara Therapeutics will host a virtual investor webinar on May 19, 2026, at 4:30 pm ET.
- The webinar will cover Lymphatic Malformations (LMs), treatment landscape, and the TARA-002 clinical program.
- Key opinion leaders will provide perspectives on disease burden and current treatments for LMs.
- TARA-002 has Rare Pediatric Disease, Orphan Drug, Breakthrough Therapy, and Fast Track designations from the FDA for LMs.
- TARA-002 is an investigational cell therapy for NMIBC and LMs, currently in a pivotal Phase 2 trial for LMs.
- Protara focuses on macrocystic and mixed cystic LMs, for which there are no currently approved therapies.
Price Impact
More from TARA